EyePoint Pharmaceuticals, Inc.·4

Mar 4, 5:40 PM ET

Ribeiro Ramiro 4

4 · EyePoint Pharmaceuticals, Inc. · Filed Mar 4, 2024

Insider Transaction Report

Form 4
Period: 2024-03-01
Ribeiro Ramiro
Chief Medical Officer
Transactions
  • Award

    Stock Option (Right to Buy)

    2024-03-01+125,000125,000 total
    Exercise: $28.00Exp: 2034-03-01Common Stock (125,000 underlying)
Footnotes (1)
  • [F1]The option to purchase will vest and become exercisable as follows: 25% at March 1st, 2025 and the remainder ratably, on a monthly basis, over the remaining three years.

Documents

1 file
  • 4
    primarydocument.xmlPrimary

    PRIMARY DOCUMENT